BioWorld

March 4, 2002

View Archived Issues

Essential Acquiring Maret For 2M Shares Of Locked-Up Stock

Essential Therapeutics Inc. on Friday said it will strengthen its clinical and preclinical pipeline through the acquisition of Maret Pharmaceuticals Inc. in a deal valued at up to about $6.8 million. (BioWorld Today) Read More

Titan Cancer Antibodies Paired In Colorectal Phase II Study

Read More

KO Mice Answer In Affirmative; Ablation Of Muc2 Gene Results In Full-Blown Colorectal Cancers

Read More

Peregrine, Oxigene End Venture On Vascular Targeting Agents

Read More

InterMune Goes To Shelf, Files To Sell 2.5M Shares

Read More

Other News To Note

Read More